Efficacy and Safety of Abatacept vs Infliximab in Rheumatoid Arthritis
Author Information
Author(s): M Schiff, M Keiserman, C Codding, S Songcharoen, A Berman, S Nayiager, C Saldate, T Li, R Aranda, J-C Becker, C Lin, P L N Cornet, M Dougados
Primary Institution: Denver Arthritis Clinic
Hypothesis
The study aims to evaluate the efficacy and safety of abatacept or infliximab compared to placebo in patients with rheumatoid arthritis who have an inadequate response to methotrexate.
Conclusion
Abatacept and infliximab showed similar efficacy, but abatacept had a better safety profile with fewer serious adverse events.
Supporting Evidence
- Abatacept showed a greater reduction in DAS28 scores compared to placebo.
- Infliximab also showed significant efficacy compared to placebo.
- Abatacept had fewer serious adverse events than infliximab over the study period.
Takeaway
This study looked at two treatments for arthritis and found that both worked well, but one was safer than the other.
Methodology
Patients with rheumatoid arthritis were randomized to receive abatacept, infliximab, or placebo, and their disease activity was measured over 12 months.
Potential Biases
Potential bias due to the study being sponsored by Bristol-Myers Squibb, the manufacturer of abatacept.
Limitations
The study did not evaluate the effect of abatacept or infliximab on radiographic progression and used a fixed dose of infliximab.
Participant Demographics
{"age":"49 years (SD 12.5)","gender":"83.3% female","race":"80.8% Caucasian"}
Statistical Information
P-Value
p<0.001
Confidence Interval
95% CI of –0.96, –0.29
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website